Highest-materiality recent filing
Net loss of $32.5M for Q2 2026 vs $25.3M in Q2 2025; R&D expenses $29.0M.
Enliven Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants
Priced 8,933,334 shares at $37.50/share and 1,733,333 pre-funded warrants at $37.499 each.
Enliven reports 61% overall MMR at 80 mg QD in Phase 1b; FDA aligns on Phase 3 design for ELVN-001
161 patients enrolled; median treatment duration 35 weeks; 76% remain on study as of March 10, 2026 cutoff.
Enliven reports Q4/FY2025 results; initial Phase 1b data for ELVN-001 shows MMR rates 47-69%
Net loss of $29.7M for Q4 2025 vs $23.2M for Q4 2024; full year net loss $103.7M vs $89.0M.
Enliven Therapeutics appoints Scott Garland to board; Phillips resigns as ELVN prepares for Phase 3
Scott Garland appointed as Class I director and Chair of Nominating and Corporate Governance Committee effective Jan 7, 2026.
Enliven Therapeutics names Richard Fair CEO; co-founder Sam Kintz becomes Head of Pipeline
Richard Fair appointed President, CEO and board member, effective December 11, 2025.
Enliven Therapeutics Q3 2025 net loss $20.1M; completed Phase 1b enrollment for ELVN-001 in CML
Completed enrollment of randomized Phase 1b cohorts of ENABLE trial of ELVN-001 in CML; on track for Phase 3 pivotal trial in 2026.
Enliven Q3 net loss $20.1M; cash $477.6M; Phase 1b enrollment completed for ELVN-001
Net loss $20.1M in Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M vs $21.3M.
Enliven reports Q2 net loss $25.3M; positive ELVN-001 Phase 1 data with 47% MMR rate
Phase 1 trial of ELVN-001 in CML: 47% cumulative MMR rate; 32% achieved MMR by 24 weeks, favorable safety.
Enliven Therapeutics prices $200M public offering of common stock and pre-funded warrants
Offering of 8.39M shares at $19.66/share and 1.78M pre-funded warrants at $19.659/warrant; gross proceeds ~$200M.
Enliven reports 47% cumulative MMR by 24 weeks for ELVN-001 in Phase 1 CML trial; well-tolerated
47% of evaluable patients (25/53) achieved MMR by 24 weeks; 32% (13/41) achieved MMR, comparing favorably to asciminib's 24% in Phase 1.
Enliven Q1 net loss $28.5M; ELVN-001 44% MMR rate at 24 weeks, cash $290M
Net loss of $28.5M for Q1 2025 vs $22.7M Q1 2024; R&D expenses $24.9M.
Enliven Therapeutics Q4 2024 net loss $23.2M; cash $313.4M; pipeline milestones set for 2025
Net loss $23.2M in Q4 2024 ($19.4M in Q4 2023); full year 2024 net loss $89.0M ($71.6M in FY2023).
Enliven Q3 net loss $23.2M; ELVN-001 Phase 1 MMR rate 44% by 24 weeks
Cash $291.8M as of Sept 30, 2024; runway into late 2026.
Cash, cash equivalents and marketable securities of $312.4M as of June 30, 2024, expected to fund operations into late 2026.
Enliven Therapeutics Q1 net loss $22.7M; ELVN-001 Phase 1 shows 44% MMR at 12 weeks
Net loss of $22.7M for Q1 2024 vs $14.7M in Q1 2023; cash, equivalents & marketable securities $320.5M.
Enliven Therapeutics reports positive Phase 1 data for ELVN-001 in CML; 44% MMR rate at 12 weeks
Cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable CML patients; 44% (4/9) in post-asciminib patients.
Enliven Therapeutics raises $90M in PIPE, extends cash runway into late 2026
Gross proceeds ~$90M from sale of 5.36M shares at $14.00 and pre-funded warrants at $13.999.
Enliven Therapeutics signs $200M ATM equity distribution agreement with Jefferies
New Sales Agreement with Jefferies allows issuance of up to $200M in common stock at 3.0% commission rate.
Enliven Therapeutics Q1 net loss $14.7M; cash $292.1M; dosed first patient in ELVN-002 Phase 1
Net loss of $14.7M for Q1 2023 vs $8.7M in Q1 2022; R&D expenses $11.9M, G&A $4.5M.
Imara completes reverse merger with Enliven; combined company to trade as ELVN
Merger closed Feb 23, 2023; exchange ratio ~0.2951; ~41.1M shares outstanding post-merger.
Stockholders approved issuance of shares for merger with Enliven Therapeutics (21.4M for, 29K against).
Imara supplements merger proxy with lawsuit update and executive compensation details
Lawsuit filed Nov 23, 2022 voluntarily dismissed Jan 19, 2023; Imara says meritless.
Imara sells PDE9 program (tovinontrine) to Cardurion for $35M upfront plus milestones
Upfront cash of $34.75M at closing plus $250K previously received; net proceeds ~$32.75M after ~$2M costs.
Imara completes sale of tovinontrine and PDE9 assets to Cardurion for $34.75M upfront
Closed asset sale on Nov 10, 2022; received $34.75M upfront cash payment from Cardurion.
Imara and Enliven hold investor call on definitive merger; Enliven to become wholly owned subsidiary
Merger agreement provides for Enliven to survive as wholly owned subsidiary of Imara via a reverse merger.
Imara to merge with Enliven; Enliven stockholders to own ~84% of combined company
Enliven valued at $324.6M plus $164.5M financing; Imara valued at net cash plus $10M.
Imara sells PDE9 program (tovinontrine) to Cardurion for $34.75M upfront plus milestones
Imara to receive $34.75M upfront at closing for tovinontrine and all PDE9 assets; plus $250k previously paid.
Imara cuts 83% of workforce, ends all pipeline programs, reviews strategic options
Workforce reduction of ~83% leaves only 6 full-time employees; substantially complete by Q2 2022.
Imara reports FY2021 net loss $51.4M; interim Phase 2b data expected April 2022
Net loss $51.4M ($2.37 per share) vs $49.2M ($3.53 per share) in FY2020; cash $90.3M at Dec 31, 2021.
Imara Q2 net loss $13.2M; IMR-687 SCD trial fully enrolled; interim data Q4 2021
Net loss $13.2M ($0.74/share) vs $10.2M ($0.59) in Q2 2020.
Imara prices $50M public offering of 8.33M shares at $6.00 each; net proceeds ~$46.8M
Offering of 8,333,333 shares priced at $6.00/share for gross proceeds of $50M.
On April 8, 2024, the Board of Directors (the “Board”) of Enliven Therapeutics, Inc. (the “Company”) appointed Lori Kunkel, MD to serve as a Class III director, with a term expiring at the Company’s 2026 annual meeting of stockholders.
On February 23, 2023, immediately prior to and effective upon the closing of the Merger, Rahul D. Ballal, Ph.D., resigned from his position as the Company’s President and Chief Executive Officer, and Michael P. Gray resigned from his position as the Company’s Chief Financial Officer and Chief Operating Officer.
David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.
David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.
David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.
David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.
David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.
David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.
On February 23, 2023, immediately prior to and effective upon the closing of the Merger, Rahul D. Ballal, Ph.D., resigned from his position as the Company’s President and Chief Executive Officer, and Michael P. Gray resigned from his position as the Company’s Chief Financial Officer and Chief Operating Officer.
David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.
Kenneth Attie, M.D., the Company’s Chief Medical Officer will separate from the Company effective April 20, 2022.
On October 21, 2021, Dr. Sara Nayeem announced that she will resign from the board of directors of IMARA Inc., effective November 15, 2021, due to a change in her employment.
Max materiality 0.95 · Median 0.60 · Most common event earnings